Clinical trial
Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases
NCT00466102 · GBG Forschungs GmbH, Other · Unknown status
Key facts
| NCT number | NCT00466102 |
|---|---|
| Title | Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases |
| Official title | RADAR: A Randomized Discontinuation Phase II Study to Determine the Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases |
| Acronym | RADAR |
| Lead sponsor | GBG Forschungs GmbH, Other |
| Collaborators | Novartis Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | RAD001, Placebo |
| Enrollment | 130 |
| Start date | Dec 1, 2006 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2012 |
| First posted | Apr 27, 2007 |
| Last update posted | Aug 30, 2012 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: